Can residual proliferative cancer burden predict long-term outcomes following neoadjuvant chemotherapy in breast cancer?
Pathology · 2025-08 · 57 (5) · 570-578
DOI: 10.1016/j.pathol.2024.11.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology, 2025-08. Verfasst von Imen Zawati und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immuno-Histo-Cytology, Salah Azaiez Institute, Tunis, Tunisia; Department of Biology, Laboratory of Biochemistry and Molecular Biology,…. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplasm, Residual. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Ministère de l’Enseignement Supérieur, de la Recherche Scientifique et des Technologies de l'Information et de la Communication, Université de Tunis El Manar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Residual proliferative cancer burden (RPCB) has been suggested as a strong predictor model of long-term outcomes in breast cancer undergoing neoadjuvant chemotherapy (NACT). In our study, we aimed to compare the prognostic value of multiple post-NACT classifications for assessing residual disease. Archival surgical specimens of 97 patients with primary breast cancer who underwent NACT were evaluated for residual cancer burden (RCB). The post-operative Ki-67 proliferation index was quantified using immunohistochemistry on post-treatment surgical excision specimens with residual disease. Then, we calculated the RPCB scores by combining the anatomical RCB index with the biological post-therapeutic Ki-67 using the Cox proportional hazard model for each parameter. Using the Kaplan-Meier method, RCBIII showed an unfavourable prognosis with worse relapse-free survival (RFS) (estimated 5-year RFS rate of 38%) than RCBI, which displayed a similarly good prognosis as pathological complete response (equal to RCB0) (estimated 5-year RFS rates of 80% and 100%, respectively) (p=0.012). The RCBII showed an intermediate prognosis (estimated 5-year RFS rate of 79%). A higher post-NACT Ki-67 (greater than cut-off 20%) had a negative impact on the overall survival and RFS (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immuno-Histo-Cytology, Salah Azaiez Institute, Tunis, Tunisia; Department of Biology, Laboratory of Biochemistry and Molecular Biology, Faculty of Sciences of Tunis, University of Tunis El Manar, Ariana, T…
- Department of Immuno-Histo-Cytology, Salah Azaiez Institute, Tunis, Tunisia.
- Department of Immuno-Histo-Cytology, Salah Azaiez Institute, Tunis, Tunisia; Laboratory of Transmission, Control and Immunobiology of Infections - LR16IPT02, Pasteur Institute of Tunis, University of Tunis, Tunis, Tunis…
- Department of Epidemiology and Community Medicine, Charles Nicoles Hospital, Tunis, Tunisia.
- Institut Pascal Clermont-Ferrand, France.
- Department of Biology, Laboratory of Biochemistry and Molecular Biology, Faculty of Sciences of Tunis, University of Tunis El Manar, Ariana, Tunisia.
Förderung
- Ministère de l’Enseignement Supérieur, de la Recherche Scientifique et des Technologies de l'Information et de la Communication
- Université de Tunis El Manar
Zitieren
APA
Zawati, I., Troujette, Y., Adouni, O., Manai, M., Nouira, M., Mekki, K., Manai, M., Rahal, K., & Gamoudi, A. (2025). Can residual proliferative cancer burden predict long-term outcomes following neoadjuvant chemotherapy in breast cancer?. Pathology, 57(5), 570-578. https://doi.org/10.1016/j.pathol.2024.11.014
Vancouver
Zawati I, Troujette Y, Adouni O, Manai M, Nouira M, Mekki K, et al. Can residual proliferative cancer burden predict long-term outcomes following neoadjuvant chemotherapy in breast cancer?. Pathology. 2025;57(5):570-578. doi:10.1016/j.pathol.2024.11.014
BibTeX
@article{Zawati2025,
author = {Zawati, Imen and Troujette, Yousra and Adouni, Olfa and Manai, Maroua and Nouira, Meriem and Mekki, Karim and Manai, Mohamed and Rahal, Khaled and Gamoudi, Amor},
title = {Can residual proliferative cancer burden predict long-term outcomes following neoadjuvant chemotherapy in breast cancer?},
journal = {Pathology},
year = {2025},
volume = {57},
number = {5},
pages = {570--578},
doi = {10.1016/j.pathol.2024.11.014}
}
EUVIMED